capecitabine has been researched along with olaparib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dackus, GM; Linn, SC; Marchetti, S; Schellens, JH; Schouten, PC; Sonke, GS; van Tinteren, H | 1 |
| Domchek, SM | 1 |
| Armstrong, A; Bannister, W; Conte, P; Degboe, A; Delaloge, S; Domchek, SM; Goessl, C; Hettle, R; Im, SA; Li, W; Masuda, N; Robson, M; Ruddy, KJ; Senkus, E; Tung, N; Xu, B | 1 |
| Goessl, C; Im, SA; Iwata, H; Li, W; Masuda, N; Ouyang, Q; Park, YH; Robson, M; Sohn, JH; Tseng, LM; Wu, W; Xu, B; Yeh, DC | 1 |
3 trial(s) available for capecitabine and olaparib
| Article | Year |
|---|---|
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Carboplatin; Clinical Protocols; Compassionate Use Trials; Disease Progression; Disease-Free Survival; Drug Dosage Calculations; Female; Genetic Predisposition to Disease; Humans; Mutation; Netherlands; Phenotype; Phthalazines; Piperazines; Receptor, ErbB-2; Research Design; Time Factors; Treatment Outcome | 2016 |
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Furans; Germ-Line Mutation; Humans; International Agencies; Ketones; Male; Middle Aged; Neoplasm Metastasis; Patient Reported Outcome Measures; Phthalazines; Piperazines; Prognosis; Quality of Life; Receptor, ErbB-2; Survival Rate; Time-to-Treatment; Vinorelbine; Young Adult | 2019 |
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Breast Neoplasms; Capecitabine; Carcinoma; Female; Furans; Gastrointestinal Diseases; Genes, BRCA1; Genes, BRCA2; Genes, erbB-2; Germ-Line Mutation; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Single-Blind Method; Vinorelbine | 2020 |
1 other study(ies) available for capecitabine and olaparib
| Article | Year |
|---|---|
The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Ketones; Mutation; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Vinblastine; Vinorelbine | 2018 |